Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis.

[1]  G. Bergers,et al.  Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects , 2000 .

[2]  J. Trapani,et al.  Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. , 2000, Current opinion in immunology.

[3]  N. Restifo.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape , 2000, Nature Medicine.

[4]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[5]  D. Green,et al.  Regulation of FasL by NF-κB and AP-1 in Fas-dependent Thymineless Death of Human Colon Carcinoma Cells* , 2000, The Journal of Biological Chemistry.

[6]  S. Moe,et al.  Opposing Effects of Transmembrane and Soluble FAS Ligand Expression on Inflammation and Tumor Cell Survival , 2000, The Journal of experimental medicine.

[7]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[8]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Fingleton,et al.  Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. , 2000, The Journal of clinical investigation.

[10]  A. Strasser,et al.  Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling Implications for Cancer Therapy , 2000 .

[11]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[12]  A. Dobrovic,et al.  Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma , 1999, British Journal of Cancer.

[13]  I. Svane,et al.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors— lessons from normal and immunodeficient mice , 1999, Medical oncology.

[14]  A. Younes,et al.  Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus. , 1999, Human pathology.

[15]  R. Offringa,et al.  Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein , 1999, The Journal of experimental medicine.

[16]  Ingo Schmitz,et al.  Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells* , 1999, The Journal of Biological Chemistry.

[17]  D. Smith,et al.  Differential activity of soluble versus cellular Fas ligand: regulation by an accessory molecule. , 1999, Cellular immunology.

[18]  F. Shanahan,et al.  Expression of Fas (CD95/APO-1) Ligand by Human Breast Cancers: Significance for Tumor Immune Privilege , 1999, Clinical Diagnostic Laboratory Immunology.

[19]  W. Dalton,et al.  Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. , 1999, Blood.

[20]  H. S. Kim,et al.  Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. , 1999, American Journal of Pathology.

[21]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.

[22]  F. Dallegri,et al.  Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. , 1999, Journal of immunology.

[23]  L. Matrisian,et al.  Differential expression of matrilysin and cyclooxygenase‐2 in intestinal and colorectal neoplasms , 1999, Molecular carcinogenesis.

[24]  L. Matrisian,et al.  The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. , 1998, Cancer research.

[25]  L. Owen-Schaub,et al.  Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis , 1998, The Journal of experimental medicine.

[26]  F. Shanahan,et al.  Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer , 1998, The Journal of pathology.

[27]  P. Walker,et al.  Tumor expression of Fas ligand (CD95L) and the consequences. , 1998, Current opinion in immunology.

[28]  D. Ferrari,et al.  Apoptosis signaling by death receptors. , 1998, European journal of biochemistry.

[29]  C. Brady,et al.  The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.

[30]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[31]  S. Nagata,et al.  Downregulation of Fas ligand by shedding , 1998, Nature Medicine.

[32]  D. Green,et al.  Fas ligand- mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease. , 1998, The Journal of clinical investigation.

[33]  R. Nagle,et al.  Cleavage of β4 Integrin by Matrilysin , 1997 .

[34]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[35]  T. Ishikawa,et al.  Matrilysin gene expression in sporadic and familial colorectal adenomas , 1997, Molecular carcinogenesis.

[36]  P. Walker,et al.  Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. , 1997, Journal of immunology.

[37]  B. Hogan,et al.  Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[39]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[40]  C. Kitanaka,et al.  Apoptosis in cancer. , 1996, Human cell.

[41]  L. Matrisian,et al.  Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. , 1996, The American journal of pathology.

[42]  A. Mes-Masson,et al.  Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice. , 1996, Oncogene.

[43]  L. Matrisian,et al.  Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. , 1996, The international journal of biochemistry & cell biology.

[44]  R. Nagle,et al.  Matrilysin expression in human prostate carcinoma , 1996, Molecular carcinogenesis.

[45]  Jack P. Witty,et al.  Expression and localization of matrix‐degrading metalloproteinases during colorectal tumorigenesis , 1994, Molecular carcinogenesis.

[46]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[47]  K. Koretz,et al.  Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium , 1994, International journal of cancer.

[48]  S. Goff,et al.  Construction and use of a safe and efficient amphotropic packaging cell line. , 1988, Virology.

[49]  J. Abecassis,et al.  The collagenase gene family in humans consists of at least four members. , 1988, The Biochemical journal.

[50]  H. Smith,et al.  Epithelial cell cultures from normal glandular tissue of mice. , 1974, Journal of the National Cancer Institute.

[51]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[52]  I. Stamenkovic,et al.  Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. , 2001, Cancer research.

[53]  T. Gajewski,et al.  The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. , 1999, Critical reviews in oncogenesis.

[54]  R. Nagle,et al.  Cleavage of beta 4 integrin by matrilysin. , 1997, Experimental cell research.

[55]  J. Ritz,et al.  Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. , 1995, Leukemia & lymphoma.

[56]  L. Matrisian,et al.  Expression and localization of the matrix metalloproteinase pump‐1 (MMP‐7) in human gastric and colon carcinomas , 1991, Molecular carcinogenesis.

[57]  Luzhe Sun,et al.  Isolation and characterization of a spontaneously transformed malignant mouse mammary epithelial cell line in culture. , 1998, Carcinogenesis.